Parker, Charles J; Kar, Santwana; Kirkpatrick, Peter.
Nat Rev Drug Discov
; 6(7): 515-6, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17715500
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Genetic variants in C5 and poor response to eculizumab.
[Successful management of orthopedic operations requiring general anesthesia in a PNH patient after introduction of eculizumab].
Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
Paroxysmal nocturnal haemoglobinuria: to prednisone or not to prednisone?--a case report of a patient previously treated with steroids for 15 yrs and significant response on eculizumab.
Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Eculizumab (Soliris) and paroxysmal nocturnal haemoglobinuria in children. When transfusions are too frequent.
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.
Paroxysmal nocturnal hemoglobinuria.
Paroxysmalis nocturnalis haemoglobinuriával szövodött várandósság ritka esete.